BRE 323
Description:
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer
Study Status: Approved
Phase Of Study:
BRE 323
Available in 1 location(s)
Description:
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer
Locations:
Florida Cancer Specialists SAC DDU
8931 Colonial Center Drive Suite 300
Fort Myers, FL 33905
USA
Get Directions
844-482-4812